Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected
Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli, et al.
Journal of Infection (2021) Vol. 83, Iss. 4, pp. 467-472
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs
Meriem Bekliz, Kenneth Adea, Pauline Vetter, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 78
Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers
Gemma Moncunill, Ruth Aguilar, Marta Ribes, et al.
EBioMedicine (2022) Vol. 75, pp. 103805-103805
Open Access | Times Cited: 67
SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene
Hyunjhung Jhun, Ho‐Young Park, Yasmin Hisham, et al.
Immune Network (2021) Vol. 21, Iss. 5
Open Access | Times Cited: 61
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1475-1475
Open Access | Times Cited: 38
Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern
Robério Amorim de Almeida Pondé
Virology (2022) Vol. 572, pp. 44-54
Open Access | Times Cited: 35
Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees
Yangyang, Xiaohua Gong, Liuqing Yang, et al.
Journal of Infection (2022) Vol. 84, Iss. 4, pp. 579-613
Open Access | Times Cited: 31
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Yao Jiang, Qian Wu, Peipei Song, et al.
Frontiers in Medicine (2022) Vol. 8
Open Access | Times Cited: 29
Genomic and epidemiological surveillance of SARS-CoV-2 variants during the pre-mass vaccination period in Botucatu, Brazil
Felipe Allan da Silva da Costa, Patrícia Akemi Assato, Karen Ingrid Tasca, et al.
Virus Genes (2025)
Open Access
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 13
Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
Anna Gidari, Samuele Sabbatini, Sabrina Bastianelli, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 354-354
Open Access | Times Cited: 3
Current Updates on Variants of SARS‐CoV‐ 2: Systematic Review
Mulat Erkihun, Bayu Ayele, Zelalem Asmare, et al.
Health Science Reports (2024) Vol. 7, Iss. 11
Open Access | Times Cited: 3
Ecological and evolutionary dynamics of multi-strain RNA viruses
Dennis N. Makau, Samantha Lycett, Matthew J. Smith, et al.
Nature Ecology & Evolution (2022) Vol. 6, Iss. 10, pp. 1414-1422
Open Access | Times Cited: 16
Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: A prospective cohort study of vaccinated and unvaccinated healthcare workers
Alessandra Luna-Muschi, Igor C. Borges, Elizabeth de Faria, et al.
Journal of Infection (2021) Vol. 84, Iss. 2, pp. 248-288
Open Access | Times Cited: 22
A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose
Guillaume Beaudoin-Bussières, Alexandra Tauzin, Katrina Dionne, et al.
Viruses (2023) Vol. 15, Iss. 6, pp. 1274-1274
Open Access | Times Cited: 8
The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
Jie Wang, Qian Zhang, Hongmei Wang, et al.
Frontiers in Bioscience-Landmark (2022) Vol. 27, Iss. 5
Open Access | Times Cited: 13
Are convalescent plasma stocks collected during former COVID‐19 waves still effective against current SARS‐CoV‐2 variants?
Daniele Focosi, Massimo Franchini, Michael J. Joyner, et al.
Vox Sanguinis (2022) Vol. 117, Iss. 5, pp. 641-646
Closed Access | Times Cited: 12
The Combination of Molnupiravir with Nirmatrelvir or GC376 has a Synergic role in the Inhibition of SARS-CoV-2 Replication in Vitro
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
(2022)
Open Access | Times Cited: 12
Novel coronavirus mutations: Vaccine development and challenges
Wan-Rong Luo, Xiaomin Wu, Wei Wang, et al.
Microbial Pathogenesis (2022) Vol. 173, pp. 105828-105828
Open Access | Times Cited: 11
The hope and hype of ellagic acid and urolithins as ligands of SARS-CoV-2 Nsp5 and inhibitors of viral replication
Elisa Bianconi, Anna Gidari, Maria Souma, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 5
Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants
Meriem Bekliz, Kenneth Adea, Pauline Vetter, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 13
Introduction and Establishment of SARS-CoV-2 Gamma Variant in New York City in Early 2021
Tetyana I. Vasylyeva, Courtney E. Fang, Michelle Su, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 12, pp. 2142-2149
Open Access | Times Cited: 8
Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles
Xinyue Chang, Xuelan Liu, Mona O. Mohsen, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 307-307
Open Access | Times Cited: 6
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients
Elisabetta Schiaroli, Anna Gidari, Giovanni Brachelente, et al.
Journal of Clinical Virology (2023) Vol. 168, pp. 105584-105584
Open Access | Times Cited: 3
Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines
Labanya Mukhopadhyay, Nivedita Gupta, Pragya D. Yadav, et al.
The Indian Journal of Medical Research (2022) Vol. 155, Iss. 1, pp. 105-122
Open Access | Times Cited: 4
Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
Juan Shi, Xiaoxiao Jin, Yan Ding, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1383-1383
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top